Research background: Breast cancer remains a major public health problem, with a high number of new cases and deaths each year. However, despite advances in research to improve this disease, there is a high rate of la...Research background: Breast cancer remains a major public health problem, with a high number of new cases and deaths each year. However, despite advances in research to improve this disease, there is a high rate of late detection, leading to diagnosis at an advanced stage and a reduced chance of survival. Objective: The aim of this study is to identify the factors associated with late detection of breast cancer in women in Sub-Saharan Africa from 2014 to 2020.Setting: This systematic review focuses on sub-Saharan Africa. Methods: We searched for articles in four databases (PubMed, Embase, Global-Health and CINAHL) between 2014 and 2020 and performed a narrative synthesis to organize and group the different factors associated with late breast cancer detection. Result: After reviewing 583 publications, 6 studies were selected, highlighting factors such as lack of awareness, knowledge gaps, difficulties in accessing health services and financial constraints associated with late breast cancer screening. The participants, who ranged in number from 20 to 1776, were mainly aged between 18 and 25, with a mean age of 25 years and 6 months. Conclusion: The analysis enabled us to identify various factors associated with late breast cancer screening. Collaboration between health professionals, community organizations and policy-makers is essential to foster an environment conducive to the prevention and early detection of breast cancer.展开更多
目的探讨曲妥珠单抗并紫杉醇新辅助化疗治疗人表皮生长因子受体2(HER2)阳性晚期局部乳腺癌(HER2positive late local breast cancer,HER2-PLLBC)的临床疗效。方法选取2012年1月至2013年12月自贡市第一人民医院收治的HER2-PLLBC女性患者7...目的探讨曲妥珠单抗并紫杉醇新辅助化疗治疗人表皮生长因子受体2(HER2)阳性晚期局部乳腺癌(HER2positive late local breast cancer,HER2-PLLBC)的临床疗效。方法选取2012年1月至2013年12月自贡市第一人民医院收治的HER2-PLLBC女性患者78例,按照随机数字表法分为试验组(n=39)和对照组(n=39),对照组行曲妥珠单抗治疗,试验组行曲妥珠单抗并多西紫杉醇治疗。比较治疗前后两组血清癌胚抗原(CEA)、糖类抗原153(CA153)、C角蛋白19片段抗原21-1(CYFRA21-1)水平;血清白介素-6(IL-6)、白介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)水平;观察两组患者肿瘤复发情况及不良反应发生率。结果治疗后,两组患者血清CEA、CA153、CYFRA21-1及IL-6、IL-8、TNF-α水平均降低,试验组血清CEA、CA153、CYFRA21-1及IL-6、IL-8、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);试验组的客观有效率58.97%(23/39)、临床获益率84.62%(33/39)均大于对照组的客观有效率30.77%(12/39)、临床获益率64.10%(25/39);复发率10.26%(4/39)小于对照组的28.21%(11/39),差异有统计学意义(P<0.05)。治疗期间,试验组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论曲妥珠单抗并紫杉醇新辅助化疗治疗HER2-PLLBC疗效显著,复发率低,安全可靠。展开更多
文摘Research background: Breast cancer remains a major public health problem, with a high number of new cases and deaths each year. However, despite advances in research to improve this disease, there is a high rate of late detection, leading to diagnosis at an advanced stage and a reduced chance of survival. Objective: The aim of this study is to identify the factors associated with late detection of breast cancer in women in Sub-Saharan Africa from 2014 to 2020.Setting: This systematic review focuses on sub-Saharan Africa. Methods: We searched for articles in four databases (PubMed, Embase, Global-Health and CINAHL) between 2014 and 2020 and performed a narrative synthesis to organize and group the different factors associated with late breast cancer detection. Result: After reviewing 583 publications, 6 studies were selected, highlighting factors such as lack of awareness, knowledge gaps, difficulties in accessing health services and financial constraints associated with late breast cancer screening. The participants, who ranged in number from 20 to 1776, were mainly aged between 18 and 25, with a mean age of 25 years and 6 months. Conclusion: The analysis enabled us to identify various factors associated with late breast cancer screening. Collaboration between health professionals, community organizations and policy-makers is essential to foster an environment conducive to the prevention and early detection of breast cancer.
文摘目的探讨曲妥珠单抗并紫杉醇新辅助化疗治疗人表皮生长因子受体2(HER2)阳性晚期局部乳腺癌(HER2positive late local breast cancer,HER2-PLLBC)的临床疗效。方法选取2012年1月至2013年12月自贡市第一人民医院收治的HER2-PLLBC女性患者78例,按照随机数字表法分为试验组(n=39)和对照组(n=39),对照组行曲妥珠单抗治疗,试验组行曲妥珠单抗并多西紫杉醇治疗。比较治疗前后两组血清癌胚抗原(CEA)、糖类抗原153(CA153)、C角蛋白19片段抗原21-1(CYFRA21-1)水平;血清白介素-6(IL-6)、白介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)水平;观察两组患者肿瘤复发情况及不良反应发生率。结果治疗后,两组患者血清CEA、CA153、CYFRA21-1及IL-6、IL-8、TNF-α水平均降低,试验组血清CEA、CA153、CYFRA21-1及IL-6、IL-8、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);试验组的客观有效率58.97%(23/39)、临床获益率84.62%(33/39)均大于对照组的客观有效率30.77%(12/39)、临床获益率64.10%(25/39);复发率10.26%(4/39)小于对照组的28.21%(11/39),差异有统计学意义(P<0.05)。治疗期间,试验组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论曲妥珠单抗并紫杉醇新辅助化疗治疗HER2-PLLBC疗效显著,复发率低,安全可靠。
